Company intelligence / Profile preview

IMBdx

Ownership: Private
Development stage: Commercial

Overview

IMBdx has successfully demonstrated the diagnostic accuracy of its AlphaLiquid liquid biopsy platform, particularly in detecting HRR gene mutations in metastatic prostate cancer patients. This technology offers a non-invasive alternative to traditional tissue biopsies.

Therapeutic areas: Oncology
Modalities: Liquid Biopsy
Industry: Molecular Diagnostics

Drug pipeline

3 assets

AlphaLiquid 100

Commercial

Indications: Multiple cancer types

2 more assets in the full pipeline.

Request access →

Partnerships

AstraZenecaInocras

Beyond the preview

Go deeper on IMBdx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMBdx.

Explore the full profile